Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Open accessThe DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune system. A third phase corresponds to a state of hypercoagulability. Finally, in the fourth stage organ injury and failure occur. Appearance of autoinflammatory/autoimmune phenomena in patients with COVID-19 calls attention for the development of new strategies for the management of life-threatening conditions in critically ill patients. Antiphospholipid syndrome, autoimmune cytopenia, Guillain-Barré syndrome and Kawasaki disease have each been reported in patients with COVID-19. Here we present a scoping review of the relevant immunological findings in COVID-19 as well as the current reports about autoinflammatory/autoimmune conditions associated with the disease. These observations have crucial therapeutic implications since immunomodulatory drugs are at present the most likely best candidates for COVID-19 therapy. Clinicians should be aware of these conditions in patients with COVID-19, and these observations should be considered in the current development of vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0498-4 · Cited by 175
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 1×
“Additional phenotypic studies showed an increased concentration of highly pro-inflammatory CCR6+ Th17 cells and a reduction in the number of CD28+ cytotoxic suppressor T and regulatory T cells [71,101].”
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., Merdji, H., Clere-Jehl, R., Schenck, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06062-x · Cited by 2,792
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
Hyperinflammatory shock in children during COVID-19 pandemic
Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N., & Theocharis, P. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31094-1 · Cited by 2,494
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M., Ciuffreda, M., Bonanomi, E., & D'Antiga, L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31103-x · Cited by 2,380
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
Jin, J.-M., Bai, P., He, W., Wu, F., Liu, X.-F., Han, D.-M., Liu, S., & Yang, J.-K. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00152 · Cited by 2,325
Baig, A. M., Khaleeq, A., Ali, U., & Syeda, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00122 · Cited by 2,207
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179 · cited 2×
“Lupus anticoagulant was negative in all three patients [43].”
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 1×
“[133], published an interesting study indicating that patients with COVID-19 and severe respiratory failure may present with a condition similar to MAS, driven by IL-1β, or to an immune dysregulation, driven by IL-6.”
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Multiorgan and Renal Tropism of SARS-CoV-2
Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2011400 · Cited by 1,775
Functional exhaustion of antiviral lymphocytes in COVID-19 patients
Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Xu, Y., & Tian, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0402-2 · Cited by 1,768 · cited 3×
“also been reported [71], as well as an increased expression of their inhibitory receptor NKG2A that likely contributes to their reduced cytolytic activity [72].”
Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102763 · Cited by 1,702
Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
Tan, L., Wang, Q., Zhang, D., Ding, J., Huang, Q., Tang, Y.-Q., Wang, Q., & Miao, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0148-4 · Cited by 1,690
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
Li, M.-Y., Li, L., Zhang, Y., & Wang, X.-S. (2020) · Infectious Diseases of Poverty · doi:10.1186/s40249-020-00662-x · Cited by 1,583
Neutrophil extracellular traps in COVID-19
Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J. A., Blair, C. N., Weber, A., Barnes, B. J., Egeblad, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138999 · Cited by 1,582
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
Interpreting Diagnostic Tests for SARS-CoV-2
Sethuraman, N., Jeremiah, S. S., & Ryo, A. (2020) · JAMA · doi:10.1001/jama.2020.8259 · Cited by 1,494
Adult haemophagocytic syndrome
Ramos-Casals, M., Brito-Zerón, P., López-Guillermo, A., Khamashta, M. A., & Bosch, X. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61048-x · Cited by 1,442
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2598-9 · Cited by 1,310
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., Sun, R., Tian, Z., Xu, X., & Wei, H. (2020) · National Science Review · doi:10.1093/nsr/nwaa041 · Cited by 1,295
Guillain–Barré Syndrome Associated with SARS-CoV-2
Toscano, G., Palmerini, F., Ravaglia, S., Ruiz, L., Invernizzi, P., Cuzzoni, M. G., Franciotta, D., Baldanti, F., Daturi, R., Postorino, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2009191 · Cited by 1,260
Tocilizumab treatment in COVID‐19: A single center experience
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25801 · Cited by 1,237
Galván Casas, C., Català, A., Carretero Hernández, G., Rodríguez‐Jiménez, P., Fernández‐Nieto, D., Rodríguez‐Villa Lario, A., Navarro Fernández, I., Ruiz‐Villaverde, R., Falkenhain‐López, D., Llamas Velasco, M., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19163 · Cited by 1,225
Sungnak, W., Huang, N., Bécavin, C., & Berg, M. (2020) · PubMed Central · Cited by 1,196
Toubiana, J., Poirault, C., Corsia, A., Bajolle, F., Fourgeaud, J., Angoulvant, F., Debray, A., Basmaci, R., Salvador, E., Biscardi, S., et al. (2020) · BMJ · doi:10.1136/bmj.m2094 · Cited by 1,144
Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia
Wang, F., Nie, J., Wang, H., Zhao, Q., Xiong, Y., Deng, L., Song, S., Ma, Z., Mo, P., & Zhang, Y. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa150 · Cited by 1,131
Belhadjer, Z., Méot, M., Bajolle, F., Khraiche, D., Legendre, A., Abakka, S., Auriau, J., Grimaud, M., Oualha, M., Beghetti, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048360 · Cited by 1,129
Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., Guo, D., Hu, W., Yang, J., Tang, Z., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1747363 · Cited by 1,076
Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples
Bullard, J., Dust, K., Funk, D., Strong, J. E., Alexander, D., Garnett, L., Boodman, C., Bello, A., Hedley, A., Schiffman, Z., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa638 · Cited by 1,075
Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China
Wang, Z., Yang, B., Li, Q., Wen, L., & Zhang, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa272 · Cited by 1,063
Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C. E., Jia, X., Nicholson, S., Catton, M., Cowie, B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0819-2 · Cited by 1,013
COVID-19: the vasculature unleashed
Teuwen, L.-A., Geldhof, V., Pasut, A., & Carmeliet, P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0343-0 · Cited by 1,008
Ahn, D.-G., Shin, H.-J., Kim, M.-H., Lee, S., Kim, H.-S., Myoung, J., Kim, B.-T., & Kim, S.-J. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2003.03011 · Cited by 1,001
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
Zang, R., Castro, M. F. G., McCune, B. T., Zeng, Q., Rothlauf, P. W., Sonnek, N. M., Liu, Z., Brulois, K. F., Wang, X., Greenberg, H. B., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc3582 · Cited by 982 · cited 1×
“[67], have shown that besides TMPRSS2, TMPRSS4 present in gut epithelial cells also contributes to enhance the localized tissue infectivity of SARS-”
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study
Du, Y., Tu, L., Zhu, P., Mu, M., Wang, R., Yang, P., Wang, X., Hu, C., Ping, R., Hu, P., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0543oc · Cited by 942
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.017 · Cited by 938
Yang, Y., Shen, C., Li, J., Yuan, J., Wei, J., Huang, F., Wang, F., Li, G., Li, Y., Xing, L., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.027 · Cited by 872
A Proposed Classification of the Immunological Diseases
McGonagle, D., & McDermott, M. F. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030297 · Cited by 840
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · cited 3×
“severe lung injury by interfering with the inflammatory response, by promoting pro-inflammatory monocyte/macrophages accumulation and their release of the pro-inflammatory cytokine IL-8 [119].”
Miller Fisher syndrome and polyneuritis cranialis in COVID-19
Gutiérrez-Ortiz, C., Méndez-Guerrero, A., Rodrigo-Rey, S., San Pedro-Murillo, E., Bermejo-Guerrero, L., Gordo-Mañas, R., de Aragón-Gómez, F., & Benito-León, J. (2020) · Neurology · doi:10.1212/wnl.0000000000009619 · Cited by 810
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Fu, Y., Cheng, Y., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00207-4 · Cited by 788
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Wu, D., & Yang, X. O. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.005 · Cited by 785
COVID-19 and Kawasaki Disease: Novel Virus and Novel Case
Jones, V. G., Mills, M., Suarez, D., Hogan, C. A., Yeh, D., Segal, J. B., Nguyen, E. L., Barsh, G. R., Maskatia, S., & Mathew, R. (2020) · Hospital Pediatrics · doi:10.1542/hpeds.2020-0123 · Cited by 766
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
The Immunology of Macrophage Activation Syndrome
Crayne, C. B., Albeituni, S., Nichols, K. E., & Cron, R. Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00119 · Cited by 633
Molecular mimicry and autoimmunity
Rojas, M., Restrepo-Jiménez, P., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Leung, P. S. C., Ansari, A. A., Gershwin, M. E., & Anaya, J.-M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.012 · Cited by 627
Self-citationThe significance of OX40 and OX40L to T‐cell biology and immune disease
Croft, M., So, T., Duan, W., & Soroosh, P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00766.x · Cited by 604
Vojdani, A., & Kharrazian, D. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108480 · Cited by 588
Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms
Smatti, M. K., Cyprian, F. S., Nasrallah, G. K., Al Thani, A. A., Almishal, R. O., & Yassine, H. M. (2019) · Viruses · doi:10.3390/v11080762 · Cited by 544
Touret, F., & de Lamballerie, X. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104762 · Cited by 541
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535 · cited 1×
“The balance between these two cell populations is critical for health [103,104].”
Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019
Xiang, F., Wang, X., He, X., Peng, Z., Yang, B., Zhang, J., Zhou, Q., Ye, H., Ma, Y., Li, H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa461 · Cited by 535
Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., & Sève, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.058 · Cited by 518
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508 · cited 1×
“Up to now, there are several reports that confirm that NAbs against RBD can interrupt the interaction between SARS-CoV-2 and ACE2, thus controlling the infection [115,118].”
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Mazzoni, A., Salvati, L., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Mencarini, J., Caporale, R., Peruzzi, B., Antonelli, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138554 · Cited by 502
Convalescent plasma in Covid-19: Possible mechanisms of action
Rojas, M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E., Rojas-Villarraga, A., Ramírez-Santana, C., Díaz-Coronado, J. C., Manrique, R., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102554 · Cited by 491
Self-citationLupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19
Bowles, L., Platton, S., Yartey, N., Dave, M., Lee, K., Hart, D. P., MacDonald, V., Green, L., Sivapalaratnam, S., Pasi, K. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2013656 · Cited by 487
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 471
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., & Galli, M. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/xcdary · Cited by 466
Chu, H., Zhou, J., Wong, B. H.-Y., Li, C., Chan, J. F.-W., Cheng, Z.-S., Yang, D., Wang, D., Lee, A. C.-Y., Li, C., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv380 · Cited by 448
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.017 · Cited by 436
Duration of Antibody Responses after Severe Acute Respiratory Syndrome
Wu, L.-P., Wang, N.-C., Chang, Y.-H., Tian, X.-Y., Na, D.-Y., Zhang, L.-Y., Zheng, L., Lan, T., Wang, L.-F., & Liang, G.-D. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1310.070576 · Cited by 426 · cited 1×
“antibodies were drastically reduced [170].”
Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2
Bao, L., Deng, W., Gao, H., Xiao, C., Liu, J., Xue, J., Lv, Q., Liu, J., Yu, P., Xu, Y., et al. (2020) · doi:10.1101/2020.03.13.990226 · Cited by 419
Zhao, Y., Qin, L., Zhang, P., Li, K., Liang, L., Sun, J., Xu, B., Dai, Y., Li, X., Zhang, C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139834 · Cited by 408
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M., Hou, J., Huang, X., Li, D., Ma, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0949-6 · Cited by 405 · cited 1×
“[112], by using the same method, confirmed this result which suggest that “the value of IgM as an early marker for the acute phase of SARS-COV-2 infection might not be on par with that in other viral infection diagnostics”.”
Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China
Tan, M., Liu, Y., Zhou, R., Deng, X., Li, F., Liang, K., & Shi, Y. (2020) · Immunology · doi:10.1111/imm.13223 · Cited by 377
Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.001 · Cited by 364 · cited 1×
“Up to now, there are several reports that confirm that NAbs against RBD can interrupt the interaction between SARS-CoV-2 and ACE2, thus controlling the infection [115,118].”
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17317-y · Cited by 361
Zheng, S. G., Wang, J., & Horwitz, D. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7112 · Cited by 356
Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report
Chen, D., Xu, W., Lei, Z., Huang, Z., Liu, J., Gao, Z., & Peng, L. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.003 · Cited by 349
Liu, F., Xu, A., Zhang, Y., Xuan, W., Yan, T., Pan, K., Yu, W., & Zhang, J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.013 · Cited by 346
Integration of B cell responses through Toll-like receptors and antigen receptors
Rawlings, D. J., Schwartz, M. A., Jackson, S. W., & Meyer-Bahlburg, A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3190 · Cited by 339
Guillain-Barré syndrome related to COVID-19 infection
Alberti, P., Beretta, S., Piatti, M., Karantzoulis, A., Piatti, M. L., Santoro, P., Viganò, M., Giovannelli, G., Pirro, F., Montisano, D. A., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000741 · Cited by 335
Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity
Quintero, O. L., Amador-Patarroyo, M. J., Montoya-Ortiz, G., Rojas-Villarraga, A., & Anaya, J.-M. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.10.003 · Cited by 328
Self-citationCOVID-19 presenting with ophthalmoparesis from cranial nerve palsy
Dinkin, M., Gao, V., Kahan, J., Bobker, S., Simonetto, M., Wechsler, P., Harpe, J., Greer, C., Mints, G., Salama, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009700 · Cited by 327
Immune Thrombocytopenic Purpura in a Patient with Covid-19
Zulfiqar, A.-A., Lorenzo-Villalba, N., Hassler, P., & Andrès, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2010472 · Cited by 319
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304
Autoimmune haemolytic anaemia associated with COVID‐19 infection
Lazarian, G., Quinquenel, A., Bellal, M., Siavellis, J., Jacquy, C., Re, D., Merabet, F., Mekinian, A., Braun, T., Damaj, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16794 · Cited by 300
Lupus anticoagulant is frequent in patients with Covid‐19
Harzallah, I., Debliquis, A., & Drénou, B. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14867 · Cited by 290
Viral Trigger for Type 1 Diabetes
Filippi, C. M., & von Herrath, M. G. (2008) · Diabetes · doi:10.2337/db07-1023 · Cited by 285
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
van de Veerdonk, F. L., Netea, M. G., van Deuren, M., van der Meer, J. W., de Mast, Q., Brüggemann, R. J., & van der Hoeven, H. (2020) · eLife · doi:10.7554/elife.57555 · Cited by 284
Liu, Y., Zhang, C., Huang, F., Yang, Y., Wang, F., Yuan, J., Zhang, Z., Qin, Y., Li, X., Zhao, D., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa037 · Cited by 269
Guillain-Barré Syndrome associated with SARS-CoV-2 infection
Virani, A., Rabold, E., Hanson, T., Haag, A., Elrufay, R., Cheema, T., Balaan, M., & Bhanot, N. (2020) · IDCases · doi:10.1016/j.idcr.2020.e00771 · Cited by 252
Homeostatic proliferation and survival of naïve and memory T cells
Boyman, O., Létourneau, S., Krieg, C., & Sprent, J. (2009) · European Journal of Immunology · doi:10.1002/eji.200939444 · Cited by 250
Autoinflammation and autoimmunity: Bridging the divide
Doria, A., Zen, M., Bettio, S., Gatto, M., Bassi, N., Nalotto, L., Ghirardello, A., Iaccarino, L., & Punzi, L. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.018 · Cited by 225
Belhadjer, Z., Méot, M., Bajolle, F., Khraiche, D., Legendre, A., Abakka, S., Auriau, J., Grimaud, M., Oualha, M., Beghetti, M., et al. (2021) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/j.acvdsp.2021.06.005 · Cited by 209
Autoreactive CD8 T Cells in Organ-Specific Autoimmunity
Liblau, R. S., Wong, F. S., Mars, L. T., & Santamaria, P. (2002) · Immunity · doi:10.1016/s1074-7613(02)00338-2 · Cited by 206
Zhang, Z., Qin, P., Deng, Y., Ma, Z., Guo, H., Guo, H., Hou, Y., Wang, S., Zou, W., Sun, Y., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1246-x · Cited by 201
Bystander activation and autoimmunity
Pacheco, Y., Acosta-Ampudia, Y., Monsalve, D. M., Chang, C., Gershwin, M. E., & Anaya, J.-M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.06.012 · Cited by 198
Self-citationGuillain‐Barr é syndrome during SARS‐CoV‐2 pandemic: A case report and review of recent literature
Scheidl, E., Canseco, D. D., Hadji‐Naumov, A., & Bereznai, B. (2020) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12382 · Cited by 185
Wang, W., Zhang, W., Zhang, J., He, J., & Zhu, F. (2020) · HLA · doi:10.1111/tan.13941 · Cited by 185
Du, S. Q., & Yuan, W. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25866 · Cited by 183
Kahlenberg, J. M., Thacker, S. G., Berthier, C. C., Cohen, C. D., Kretzler, M., & Kaplan, M. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101284 · Cited by 179
Ottaviani, D., Boso, F., Tranquillini, E., Gapeni, I., Pedrotti, G., Cozzio, S., Guarrera, G. M., & Giometto, B. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04449-8 · Cited by 179
IL-1β Breaks Tolerance through Expansion of CD25+ Effector T Cells
O’Sullivan, B. J., Thomas, H. E., Pai, S., Santamaria, P., Iwakura, Y., Steptoe, R. J., Kay, T. W. H., & Thomas, R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7278 · Cited by 164
Macrophage activation syndrome and cytokine-directed therapies
Schulert, G. S., & Grom, A. A. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.03.002 · Cited by 163
COVID‐19‐associated immune thrombocytopenia
Bomhof, G., Mutsaers, P. G. N. J., Leebeek, F. W. G., te Boekhorst, P. A. W., Hofland, J., Croles, F. N., & Jansen, A. J. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16850 · Cited by 161
Guillain–Barré syndrome, transverse myelitis and infectious diseases
Rodríguez, Y., Rojas, M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Monsalve, D. M., Gershwin, M. E., & Anaya, J.-M. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.142 · Cited by 159
Self-citationSARS-CoV-2 infection among patients with systemic autoimmune diseases
Emmi, G., Bettiol, A., Mattioli, I., Silvestri, E., Scala, G. D., Urban, M. L., Vaglio, A., & Prisco, D. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102575 · Cited by 158
Gray, J. I., Westerhof, L. M., & MacLeod, M. K. L. (2018) · Immunology · doi:10.1111/imm.12929 · Cited by 152
SARS-CoV-2 shedding and infectivity
Atkinson, B., & Petersen, E. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30868-0 · Cited by 146
On the molecular determinants of the SARS-CoV-2 attack
Kanduc, D., & Shoenfeld, Y. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108426 · Cited by 144
Rowley, A. H., Baker, S. C., Shulman, S. T., Rand, K. H., Tretiakova, M., Perlman, E. J., Garcia, F. L., Tajuddin, N. F., Fox, L. M., Huang, J. H., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq136 · Cited by 142
Braciale, T. J., & Hahn, Y. S. (2013) · Immunological Reviews · doi:10.1111/imr.12109 · Cited by 135
Gorse, G. J., Donovan, M. M., & Patel, G. B. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25715 · Cited by 134
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
Ceribelli, A., Motta, F., Santis, M. D., Ansari, A. A., Ridgway, W. M., Gershwin, M. E., & Selmi, C. F. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102442 · Cited by 131
Self-citationGuilpain, P., Bihan, C. L., Foulongne, V., Taourel, P., Pansu, N., Maria, A. T. J., Jung, B., Larcher, R., Klouche, K., & Moing, V. L. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217549 · Cited by 131
T cell homeostasis and systemic autoimmunity
Theofilopoulos, A. N., Dummer, W., & Kono, D. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12173 · Cited by 130
A causal link between lymphopenia and autoimmunity
Khoruts, A., & Fraser, J. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2004.10.022 · Cited by 129
Caamaño, D. S. J., & Beato, R. A. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.05.016 · Cited by 128
The Role of Cytokines in the Pathogenesis and Treatment of Systemic Lupus Erythematosus
Davis, L., Hutcheson, J., & Mohan, C. (2011) · Journal of Interferon and Cytokine Research · doi:10.1089/jir.2011.0047 · Cited by 121
Macrophage Activation Syndrome in Autoimmune Disease
Deane, S., Selmi, C., Teuber, S., & Gershwin, M. (2010) · International Archives of Allergy and Immunology · doi:10.1159/000312628 · Cited by 119
Self-citationGuillain-Barré syndrome as a complication of SARS-CoV-2 infection
Coen, M., Jeanson, G., Almeida, L., Hübers, A., Stierlin, F., Najjar, I., Ongaro, M., Moulin, K., Makrygianni, M., Leemann, B., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.074 · Cited by 117
Simultaneous onset of COVID‐19 and autoimmune haemolytic anaemia
Lopez, C., Kim, J., Pandey, A., Huang, T., & DeLoughery, T. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16786 · Cited by 112
Cranial neuropathies and COVID-19: Neurotropism and autoimmunity
Costello, F., & Dalakas, M. C. (2020) · Neurology · doi:10.1212/wnl.0000000000009921 · Cited by 112
Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons
Lucchese, G., & Flöel, A. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102556 · Cited by 109
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Fafi-Kremer, S., Bruel, T., Madec, Y., Grant, R., Tondeur, L., Grzelak, L., Staropoli, I., Anna, F., Souque, P., Fernandes-Pellerin, S., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102915 · Cited by 108 · cited 3×
“The identification of anti-SARSCoV-2 antibodies in recovered patients, which can bind and neutralize the virus, supports the use of convalescent plasma (CP), as a therapeutic approach of artificial passive immunity [113,117].”
Autoimmune effector memory T cells: the bad and the good
Devarajan, P., & Chen, Z. (2013) · Immunologic Research · doi:10.1007/s12026-013-8448-1 · Cited by 105
IL-6 blocks a discrete early step in lymphopoiesis
Maeda, K., Baba, Y., Nagai, Y., Miyazaki, K., Malykhin, A., Nakamura, K., Kincade, P. W., Sakaguchi, N., & Coggeshall, K. M. (2005) · Blood · doi:10.1182/blood-2005-02-0456 · Cited by 101
Lymphopenia and autoimmune diseases.
Schulze‐Koops, H. (2004) · Arthritis Research · doi:10.1186/ar1208 · Cited by 98
Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease
Aguiar, C. L., & Erkan, D. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13502919 · Cited by 97
Ellinghaus, D., Degenhardt, F. C., Bujanda, L., Buti, M., Albillos, A., Invernizzi, P., Fernández, J., Prati, D., Baselli, G., Asselta, R., et al. (2020) · medRxiv · doi:10.1101/2020.05.31.20114991 · Cited by 95
Patterson, B. K., Seethamraju, H., Dhody, K., Corley, M. J., Kazempour, K., Lalezari, J., Pang, A. P. S., Sugai, C., Francisco, E. B., Pise, A., et al. (2020) · medRxiv · doi:10.1101/2020.05.02.20084673 · Cited by 92
Atypical presentation of COVID-19 in young infants
Nathan, N., Prévost, B., & Corvol, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30980-6 · Cited by 90
Lokman, S. M., Rasheduzzaman, M., Salauddin, A., Barua, R., Tanzina, A. Y., Rumi, M. H., Hossain, M. I., Siddiki, A. Z., Mannan, A., & Hasan, M. M. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104389 · Cited by 90
Zhu, Y., Zhu, G., Luo, L., Flies, A. S., & Chen, L. (2007) · Blood · doi:10.1182/blood-2006-10-043463 · Cited by 89
Tocilizumab for rheumatoid arthritis
Singh, J. A., Beg, S., & Lopez-Olivo, M. A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008331.pub2 · Cited by 89
Post SARS-CoV-2 Guillain-Barré syndrome
Arnaud, S., Budowski, C., Tin, S. N. W., & Degos, B. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.05.003 · Cited by 84
Generali, E., Bose, T., Selmi, C. F., Voncken, J. W., & Damoiseaux, J. G. M. C. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.002 · Cited by 83
Self-citationDuret, P., Sebbag, E., Mallick, A., Gravier, S., Spielmann, L., & Messer, L. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217362 · Cited by 82
Raucci, F., Mansour, A. A., Casillo, G. M., Saviano, A., Caso, F., Scarpa, R., Mascolo, N., Iqbal, A. J., & Μaione, F. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102572 · Cited by 79
Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease
Franco, A., Shimizu, C., Tremoulet, A. H., & Burns, J. C. (2010) · Autoimmunity · doi:10.3109/08916930903405891 · Cited by 77
Cameron, M. J., Kelvin, A. A., Leon, A. J., Cameron, C., Ran, L., Xu, L., Chu, Y.-K., Danesh, A., Yuan, F., Li, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045842 · Cited by 71
Cocapture of cognate and bystander antigens can activate autoreactive B cells
Sanderson, N., Zimmermann, M., Eilinger, L., Gubser, C., Schaeren‐Wiemers, N., Lindberg, R. L. P., Dougan, S. K., Ploegh, H. L., Kappos, L., & Derfuss, T. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614472114 · Cited by 69
Sex Differences in Disease Severity Among Patients With Systemic Lupus Erythematosus
Crosslin, K. L., & Wiginton, K. L. (2011) · Gender Medicine · doi:10.1016/j.genm.2011.10.003 · Cited by 68
Clay, C., Donart, N., Fomukong, N., Knight, J. B., Lei, W., Price, L., Hahn, F., Van Westrienen, J., & Harrod, K. S. (2012) · Journal of Virology · doi:10.1128/jvi.06791-11 · Cited by 64
Fernández-Cooke, E., Tascón, A. B., Sánchez-Manubens, J., Antón, J., Grasa, C. D., Santos, J. A., Pinto, E. V., Clemente, D., Rodríguez, B. M., Alonso, M. B., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215665 · Cited by 64
Genetics and Vaccines in the Era of Personalized Medicine
Castiblanco, J., & Anaya, J. (2014) · Current Genomics · doi:10.2174/1389202916666141223220551 · Cited by 59
Self-citationBiological treatment in adult-onset Still's disease
Pouchot, J., & Arlet, J. (2012) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.07.002 · Cited by 57
COVID-19 in rheumatic disease patients on immunosuppressive agents
Sharmeen, S., Elghawy, A. A., Zarlasht, F., & Yao, Q. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.05.010 · Cited by 57
From autoinflammation to autoimmunity: old and recent findings
Caso, F., Costa, L., Nucera, V., Barilaro, G., Masala, I. F., Talotta, R., Caso, P., Scarpa, R., Sarzi‐Puttini, P., & Atzeni, F. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4209-9 · Cited by 54
Zeng, Q., Li, Y., Huang, G., Wu, W., Dong, S.-Y., & Xu, Y. (2020) · medRxiv · doi:10.1101/2020.03.08.20031229 · Cited by 50
COVID-19: the new challenge for rheumatologists. First update
Ferro, F., Elefante, E., Puxeddu, I., Baldini, C., Bartoloni, E., Baratè, C., Galimberti, S., Talarico, R., Mosca, M., & Bombardieri, S. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/yvn0nh · Cited by 43
Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease
Li, S., Zheng, S., Tang, S., Pan, Y., Zhang, S., Fang, H., & Qiao, J. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08747-8 · Cited by 42
Thrombocytopenia as an initial manifestation of COVID‐19; case series and literature review
Ahmed, M. Z., Khakwani, M. Z., Venkatadasari, I., Horgan, C., Giles, H. V., Jobanputra, S., Lokare, A., Ewing, J. C., Paneesha, S., & Murthy, V. (2020) · British Journal of Haematology · doi:10.1111/bjh.16769 · Cited by 39
COVID-19: the new challenge for rheumatologists
Belov, B. S., & Karateev, A. E. (2020) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2020-2-110-116 · Cited by 32
Signaling Through gp130 Compromises Suppressive Function in Human FOXP3+ Regulatory T Cells
Dhuban, K. B., Bartolucci, S., d'Hennezel, E. B., & Piccirillo, C. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01532 · Cited by 27
Rigamonti, C., Cittone, M. G., Benedittis, C. D., Rizzi, E., Casciaro, G. F., Bellan, M., Sainaghi, P. P., & Pirisi, M. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.047 · Cited by 24
Piccirillo, M. C., Ascierto, P. A., Atripaldi, L. G., Cascella, M., Costantini, M., Dolci, G., Facciolongo, N. C., Fraganza, F., Marata, A. M., Massari, M., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106165 · Cited by 14
Cytokines in Cytokine Storm Syndrome
Behrens, E. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-22094-5_12 · Cited by 12
Sex hormones and gender disparity in immunity and autoimmunity
Ortona, E., Delunardo, F., Maselli, A., Pierdominici, M., & Malorni, W. (2015) · Italian Journal of Gender-Specific Medicine · Cited by 10
Cited by
The SARS-CoV-2 as an instrumental trigger of autoimmunity
Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G., & Shoenfeld, Y. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102792 · Cited by 494
Kedor, C., Freitag, H., Meyer-Arndt, L., Wittke, K., Hanitsch, L. G., Zoller, T., Steinbeis, F., Haffke, M., Rudolf, G., Heidecker, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32507-6 · Cited by 405
Inducing immune tolerance with dendritic cell-targeting nanomedicines
Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R., & Voelcker, N. H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00810-2 · Cited by 297
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Gusev, E., Sarapultsev, A., Solomatina, L., & Chereshnev, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031716 · Cited by 281
Metadata
- Authors
- Rodríguez, Y., Novelli, L., Rojas, M., De Santis, M., Acosta-Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., Gershwin, M. E., Selmi, C., & Anaya, J.-M.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 114
- Pages
- 102506
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W3034241701
- Cited by
- 312
- References
- 173
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.